Compare FLY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.1B |
| IPO Year | N/A | 2020 |
| Metric | FLY | PRAX |
|---|---|---|
| Price | $27.28 | $302.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $38.88 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 8.8M | 531.7K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $174.79 | N/A |
| Revenue Next Year | $66.73 | $7,758.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.00 | $37.25 |
| 52 Week High | $62.17 | $366.52 |
| Indicator | FLY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 53.66 |
| Support Level | $18.95 | $282.49 |
| Resistance Level | $28.74 | $327.65 |
| Average True Range (ATR) | 3.91 | 17.76 |
| MACD | -1.37 | 5.20 |
| Stochastic Oscillator | 0.23 | 92.68 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.